No Data
No Data
Truist Financial Maintains Argenx SE(ARGX.US) With Buy Rating
Argenx Says New Data on Its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'
Argenx SE Shows Promising Immunology Program Results
Argenx Highlights Patient Impact Data Across Immunology Programs At 2024 AANEM And MGFA Scientific Session
Raymond James Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $605
Express News | Raymond James Reinstates Strong Buy on Argenx, Announces $605 Price Target
No Data
No Data